Very true. The crystal ball on successful proof of additional conditions is a bit murky right now. From a statistical point of view, I'm figuring at least 50% of the "Cancer-22" trials go with Leronlimab as new SOC. The NASH, mTNBC, and GvHD are almost slam dunk with no real competition out there.
The others???...hopefully the crystal ball with begin to clear up when the SP goes north of $25.
Market Data 
Markets 
